Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Recruiting
Observational Study
Autoimmune Lymphoproliferative Syndrome
Autoimmune Cytopenia
Autoimmune Diseases
Autoimmune Anemia
Autoimmune Thrombocytopenia
Autoimmune Hepatitis
Autoimmune Diabetes
Autoimmune Rheumatologic Disease
Systemic Lupus Erythematosus
Juvenile Idiopathic Arthritis
Hemophagocytic Lymphohistiocytoses
EBV Lymphoproliferation
RAS-Associated Autoimmune Leucoproliferative Disease
Primary Immunodeficiency
APECED
IPEX
BENTA
Enteropathy, Autoimmune
Combined Immunodeficiency
IBD
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 1 – 18
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria for controls (patients relatives and unrelated subjects):
* Individuals aged\<18 y/o.
* Individuals \> 6 kg
* Individuals not affected by an immune-related disease or not affected by cancer
* Individuals whose parents have signed an enlightened consent.
Inclusion criteria for pa…
Contacts